Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Platelet-derived β2M regulates monocyte inflammatory responses
Zachary T. Hilt, Daphne N. Pariser, Sara K. Ture, Amy Mohan, Pearl Quijada, Akua A. Asante, Scott J. Cameron, Julie A. Sterling, Alyssa R. Merkel, Andrew L. Johanson, Jermaine L. Jenkins, Eric M. Small, Kathleen E. McGrath, James Palis, Michael R. Elliott, Craig N. Morrell
Zachary T. Hilt, Daphne N. Pariser, Sara K. Ture, Amy Mohan, Pearl Quijada, Akua A. Asante, Scott J. Cameron, Julie A. Sterling, Alyssa R. Merkel, Andrew L. Johanson, Jermaine L. Jenkins, Eric M. Small, Kathleen E. McGrath, James Palis, Michael R. Elliott, Craig N. Morrell
View: Text | PDF
Research Article Vascular biology

Platelet-derived β2M regulates monocyte inflammatory responses

  • Text
  • PDF
Abstract

β-2 Microglobulin (β2M) is a molecular chaperone for the major histocompatibility class I (MHC I) complex, hemochromatosis factor protein (HFE), and the neonatal Fc receptor (FcRn), but β2M may also have less understood chaperone-independent functions. Elevated plasma β2M has a direct role in neurocognitive decline and is a risk factor for adverse cardiovascular events. β2M mRNA is present in platelets at very high levels, and β2M is part of the activated platelet releasate. In addition to their more well-studied thrombotic functions, platelets are important immune regulatory cells that release inflammatory molecules and contribute to leukocyte trafficking, activation, and differentiation. We have now found that platelet-derived β2M is a mediator of monocyte proinflammatory differentiation through noncanonical TGFβ receptor signaling. Circulating monocytes from mice lacking β2M only in platelets (Plt-β2M–/–) had a more proreparative monocyte phenotype, in part dependent on increased platelet-derived TGFβ signaling in the absence of β2M. Using a mouse myocardial infarction (MI) model, Plt-β2M–/– mice had limited post-MI proinflammatory monocyte responses and, instead, demonstrated early proreparative monocyte differentiation, profibrotic myofibroblast responses, and a rapid decline in heart function compared with WT mice. These data demonstrate a potentially novel chaperone-independent, monocyte phenotype–regulatory function for platelet β2M and that platelet-derived 2M and TGFβ have opposing roles in monocyte differentiation that may be important in tissue injury responses.

Authors

Zachary T. Hilt, Daphne N. Pariser, Sara K. Ture, Amy Mohan, Pearl Quijada, Akua A. Asante, Scott J. Cameron, Julie A. Sterling, Alyssa R. Merkel, Andrew L. Johanson, Jermaine L. Jenkins, Eric M. Small, Kathleen E. McGrath, James Palis, Michael R. Elliott, Craig N. Morrell

×

Figure 5

β2M signals through a noncanonical TGFβ receptor signaling mechanism.

Options: View larger image (or click on image) Download as PowerPoint
β2M signals through a noncanonical TGFβ receptor signaling mechanism.
(A...
(A) Inhibition of TAK1 (7-ox, 1 μM) blocked β2M-induced THP-1 IL-8 but had no effect on β2M-induced SMAD3 activation (P-SMAD3). THP-1 cells were treated with TAK1 inhibitor or control buffer prior to β2M. IL-8 was determined by ELISA (n = 4; **P < 0.01 vs. control, 1-way ANOVA with Bonferroni correction), and P-SMAD3 and total SMAD3 were determined by immunoblot (representative image quantified in Supplemental Figure 12 and 13). (B) JNK inhibitor (SP600125, 10 μM) greatly attenuated THP-1 IL-8 production, but p38 inhibitor (SB202190, 10 μM) only partially attenuated IL-8 (both panels, n = 4, **P < 0.01 vs. control, 1-way ANOVA with Bonferroni correction). (C) β2M-induced WT but not TGFβR2–/– monocyte p-JNK. WT and TGFβR2–/– monocytes were incubated with control buffer or β2M, and intracellular p-JNK was determined by flow cytometry (n = 4, *P < 0.05, unpaired 2-tailed t test with Welch’s correction). (D and E) Blocking β2M oligomer formation with NEM inhibited β2M induced monocyte inflammatory phenotype. β2M was pretreated with buffer or NEM and then added to mouse monocytes for 48 hours. (D) NEM reduced β2M oligomer formation (nonreducing gel), and (E) Ly6Chi monocytes (n = 4, *P < 0.05, 1-way ANOVA with Bonferroni correction).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts